FDA Panel Reviews Galleri Multi-Cancer Blood Test: What the Vote Means
Estimated read time: 4 minutes
On September 23, 2026, the U.S. Food and Drug Administration convened its Molecular and Clinical Genetics Panel to review a premarket approval application for Galleri, a prescription multi-cancer detection blood test made by GRAIL.
The meeting was a major regulatory milestone, but it did not make the test FDA approved. Advisory committees provide independent expert advice. Their recommendations are nonbinding, and FDA makes the regulatory decision after reviewing the full application.
What Galleri is designed to do
Galleri analyzes cell-free DNA in blood for methylation patterns associated with cancer. Under the proposed indication, it would be used to screen adults age 50 and older. The test reports either “Cancer Signal Detected” or “No Cancer Signal Detected.” When a signal is detected, it also predicts the likely location where that signal originated.
That result is a screening result, not a diagnosis. A positive result requires diagnostic imaging, procedures, or other testing directed by a qualified clinician. A negative result does not rule out cancer.
The proposed labeling also states that Galleri is not a replacement for established single-cancer screening. People would still need mammography, colorectal screening, lung screening, cervical screening, prostate screening discussions, and other care recommended for their age and risk.
What the panel voted
According to FDA’s 24-hour meeting summary, the 10-member panel voted unanimously that the data provided reasonable assurance of safety for people who meet the proposed criteria, assuming adequate instructions, labeling, and education.
The effectiveness vote was closer: 6 yes, 4 no, with no abstentions. Panelists who supported effectiveness emphasized potential value for cancers that do not have guideline-recommended screening. Some support depended on removing the word “early” from the proposed claim and requiring additional study.
On whether benefits outweighed risks, the panel voted 7 yes, 2 no, and 1 abstention. Supporters generally called for post-approval research, clear labeling, and strong education for patients and clinicians. Dissenting panelists cited uncertainty about whether cancers detected by the test would translate into meaningful improvements in long-term patient outcomes.
Those votes are important evidence of expert opinion, but they are not a final FDA decision.
What evidence the panel reviewed
FDA’s executive summary describes evidence from two human clinical studies, PATHFINDER 2 and NHS-Galleri. These were not laboratory-only or animal studies; they evaluated test performance in people. FDA reviewed measures including sensitivity, specificity, positive predictive value, negative predictive value, performance by cancer type, and performance by stage.
The panel saw the greatest potential value in finding signals from cancers that lack routine screening programs. At the same time, members noted substantial variation in sensitivity among cancer types. For some cancers, the studies observed too few cases to support firm conclusions.
Several panelists also questioned whether the broad phrase “early detection” was supported. The panel summary says the test generally detected stage I cancers less often than cancers at stages II through IV. Some cancers may still be detected before they would otherwise come to clinical attention, but that is not the same as proving that the test consistently finds cancers at an early stage.
The benefits and risks that remain uncertain
A multi-cancer blood test is less invasive than many diagnostic procedures and may identify signals from cancers for which no recommended screening test exists. Those possibilities explain much of the interest.
The potential harms are also real. A false positive can lead to anxiety, imaging, biopsies, or other procedures that do not find cancer. A false negative can create false reassurance or delay evaluation. Performance may differ by cancer type, stage, demographic group, and clinical history.
Most importantly, the long-term effect on outcomes has not been established. Detecting more cancer signals does not automatically prove that a screening program prevents cancer deaths or improves quality of life. The panel recommended continued follow-up, real-world performance monitoring, study of testing intervals, and additional evidence across demographic groups.
What this means for patients now
The FDA meeting does not create a new screening recommendation, and the panel vote does not replace a conversation with a clinician. People should continue all guideline-recommended cancer screening based on age, anatomy, smoking history, family history, and other risk factors.
Anyone considering a multi-cancer detection test should ask what a positive result would trigger, how a negative result should be interpreted, whether insurance covers follow-up, and which established screening tests remain due. The answer to the last question should not be “none.”
The bottom line
The FDA advisory panel viewed Galleri as promising enough to support safety unanimously and effectiveness and benefit-risk by narrower majorities. It also identified meaningful uncertainty about variable performance, the “early detection” claim, false results, follow-up, and long-term outcomes. Until FDA issues a final decision, the accurate description is simple: the application is under review, the panel has voted, and the test is not FDA approved.
References
U.S. Food and Drug Administration. September 23, 2026 Molecular and Clinical Genetics Panel meeting announcement and materials. https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting
U.S. Food and Drug Administration. FDA Executive Summary: GRAIL Inc., Galleri. https://www.fda.gov/media/194909/download
U.S. Food and Drug Administration. September 23, 2026 panel 24-hour summary. https://www.fda.gov/media/195032/download
This content is for educational purposes only and is not a substitute for professional medical advice.